tolvaptan has been researched along with ARPKD in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Cadnapaphornchai, MA; Goldstein, SL; Greenbaum, LA; Guay-Woodford, LM; Liebau, MC; Litwin, M; Mekahli, D; Schaefer, F; Seeman, T | 1 |
| Bennett, WM | 1 |
| Gattone, V; Harris, PC; Torres, VE; Wang, X | 1 |
3 other study(ies) available for tolvaptan and ARPKD
| Article | Year |
|---|---|
Design of two ongoing clinical trials of tolvaptan in the treatment of pediatric patients with autosomal recessive polycystic kidney disease.
Topics: Antidiuretic Hormone Receptor Antagonists; Child; Cysts; Humans; Infant, Newborn; Kidney; Longitudinal Studies; Polycystic Kidney, Autosomal Dominant; Polycystic Kidney, Autosomal Recessive; Tolvaptan | 2023 |
V2 receptor antagonists in cystic kidney diseases: an exciting step towards a practical treatment.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Humans; Kidney Diseases, Cystic; Polycystic Kidney, Autosomal Dominant; Polycystic Kidney, Autosomal Recessive; Tolvaptan | 2005 |
Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat.
Topics: Adenine; Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cyclic AMP; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Female; Guanosine Triphosphate; Introns; Kidney; Male; Phosphorylation; Polycystic Kidney Diseases; Polycystic Kidney, Autosomal Recessive; Proto-Oncogene Proteins B-raf; ras Proteins; Rats; Rats, Sprague-Dawley; Receptors, Cell Surface; Thymine; Tolvaptan | 2005 |